BRIUMVI®

This promotional website is intended for UK healthcare professionals.

efficacy meets efficiency
The first anti-CD20 therapy for multiple sclerosis to
achieve an ARR <0.1 in two phase 3 clinical trials²

Briumvi® (ublituximab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.¹

Glyco-engineered design

BRIUMVI® is a CD20-directed cytolytic antibody that is designed for improved targeting of B cells^3,4

Convenient administration

BRIUMVI® is administered as a 1-hour infusion, twice per year.^1,aIn clinical trials, 95% of all BRIUMVI® 1-hour infusion
were delivered without interruption.⁵

Proven efficacy

BRIUMVI® significantly reduced relapse rates and T1 and T2 lesions vs teriflunomide in clinical trials.¹

It is the first anti-CD20 therapy for multiple sclerosis to achieve an ARR of <0.1 in two phase 3 clinical trials.^1,2,b

Safety profile well established safety profile

The most important and frequently reported adverse reactions with BRIUMVI® are infusion-related reactions (45.3%) and infections (55.8%).¹ In active-controlled RMS trials, the overall infection rates across both arms were similar for BRIUMVI® (55.8%) and teriflunomide (54.4%) treated patients. The infections were predominantly mild to moderate in severity.¹

Looking for an educational resource on BRIUMVI® to provide to your patients?

BRIUMVI® (ublituximab) 150 mg concentrate for solution for infusion

BRIUMVI® (ublituximab) is indicated for the treatment of adult patients with relapsing forms of MS (RMS) with active disease defined by clinical or imaging features.¹

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Neuraxpharm by email: info-uk@neuraxpharm.com.

NXUK/0225/02 Date of preparation: October 2025

^aFollowing the starting dose. Day 1 infusion is 150 mg over 4 hours; Day 15 infusion is 450 mg over 1 hour; subsequent infusions are 450 mg over 1 hour, every 24 weeks. Infusion duration may take longer if the infusion is interrupted or slowed.¹

^bARR for BRIUMVI® observed in the ULTIMATE I and II phase 3 trials.² Cross-trial comparisons are not appropriate given variation in patient populations enrolled across different trials.

References
¹BRIUMVI® Summary of Product Characteristics.
2Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704-714. doi:10.1056/NEJMoa2201904.
³Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–429. doi:10.1177/1352458520918375.
4de Romeuf C, Dutertre C-A, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008;140(6):635–643. doi:10.1111/j.1365-2141.2007.06974.x.
5Fox EJ, Steinman L, Hartung H-P, et al. Infusion-related reactions (IRRs) with ublituximab in patients with relapsing multiple sclerosis (RMS): post hoc analyses from the phase 3 ULTIMATE I and II studies. Presented at the 74th Annual Meeting of the American Academy of Neurology, 2–7 April 2022, Seattle, WA, USA.

Abbreviations
ARR, annualised relapse rate; EU, European Union; RMS, relapsing forms of multiple sclerosis; SmPC, summary of product characteristics.